<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:03:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7314813" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7314813</identifier>
        <datestamp>2020-06-26</datestamp>
        <setSpec>scirep</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
              <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
              <journal-title-group>
                <journal-title>Scientific Reports</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-2322</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7314813</article-id>
              <article-id pub-id-type="pmcid">PMC7314813</article-id>
              <article-id pub-id-type="pmc-uid">7314813</article-id>
              <article-id pub-id-type="pmid">32581313</article-id>
              <article-id pub-id-type="publisher-id">66962</article-id>
              <article-id pub-id-type="doi">10.1038/s41598-020-66962-2</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of an antioxidant supplement containing high dose lutein and zeaxanthin on macular pigment and skin carotenoid levels</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Obana</surname>
                    <given-names>Akira</given-names>
                  </name>
                  <address>
                    <email>obana@sis.seirei.or.jp</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gohto</surname>
                    <given-names>Yuko</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nakazawa</surname>
                    <given-names>Risa</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moriyama</surname>
                    <given-names>Takanobu</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gellermann</surname>
                    <given-names>Werner</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bernstein</surname>
                    <given-names>Paul S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0377 8408</institution-id><institution-id institution-id-type="GRID">grid.415466.4</institution-id><institution>Department of Ophthalmology, </institution><institution>Seirei Hamamatsu General Hospital, </institution></institution-wrap>Hamamatsu, Shizuoka Japan </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.505613.4</institution-id><institution>Hamamatsu BioPhotonics Innovation Chair, Institute for Medical Photonics Research, Preeminent Medical Photonics Education &amp; Research Center, </institution><institution>Hamamatsu University School of Medicine, </institution></institution-wrap>Hamamatsu, Shizuoka Japan </aff>
                <aff id="Aff3"><label>3</label>Longevity Link Corporation, Salt Lake City, UT United States of America </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2193 0096</institution-id><institution-id institution-id-type="GRID">grid.223827.e</institution-id><institution>Department of Ophthalmology and Visual Sciences, Moran Eye Center, </institution><institution>University of Utah School of Medicine, </institution></institution-wrap>Salt Lake City, Utah United States of America </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>6</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>6</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>10</volume>
              <elocation-id>10262</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>1</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">The effect of a high dose lutein/zeaxanthin supplement on macular pigment optical density (MPOD) and skin carotenoid (SC) levels in healthy subjects was investigated. This is a prospective, single-arm, open-label study. Subjects were 16 Japanese, age 26–57 years. Subjects took a supplement containing 20 mg/day of lutein, 4 mg/day of zeaxanthin, and other antioxidants (vitamin C, vitamin E, zinc, copper) for 16 weeks. MPOD levels were measured by a two-wavelength autofluorescence imaging technique. SC levels were measured by reflection spectroscopy. Total volume of MPOD within 9° eccentricity significantly increased by week 8 and continued to increase until week 16 (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA). The increase rate of MPOD was significantly higher in subjects with body mass index (BMI) less than 25 kg/m<sup>2</sup> (n = 13) compared to those of 25 kg/m<sup>2</sup> and higher (n = 3). SC levels increased significantly by week 4 and continued to increase until week 16 (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA). All subjects completed the study without any serious adverse events. These results demonstrated the effectiveness of a high dose lutein/zeaxanthin supplement for MPOD volume and SC levels without serious adverse events.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Health care</kwd>
                <kwd>Medical research</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par2">The human macula contains yellow pigment, called macular pigment (MP), consisting of three carotenoids, lutein ((3R, 3′R, 6′R) -lutein), zeaxanthin ((3R, 3′R) -zeaxanthin), and <italic>meso</italic>-zeaxanthin ((3R, 3′S; <italic>meso</italic>) –zeaxanthin)<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. MP absorbs blue light and acts as a filter that may attenuate photochemical damage to the retina due to blue light exposure and potentially protects against light-induced oxidative damage in the retina by quenching oxygen radicals<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref></sup>. MP functions to improve contrast sensitivity and reduces night glare<sup><xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR9">9</xref></sup>. Some studies have reported that MP optical density (MPOD) levels in eyes with age-related macular degeneration (AMD) are significantly lower than those in normal, healthy eyes<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. The light protection effect of MP is thought to prevent age-related macular degeneration (AMD)<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR15">15</xref></sup>, and our previous study on a Japanese population indicated that lower MPOD levels may be a risk factor for AMD progression<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>.</p>
              <p id="Par3">Carotenoids such as lycopene, alpha-. beta-, gamma-, delta-carotene, beta-cryptoxanthin, lutein, and zeaxanthin are contained in the epidermis, dermis, and subcutaneous fat<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. These carotenoids protect skin against oxidation induced by sunlight exposure. Lutein and zeaxanthin have been reported to reduce lipid peroxidation and increase moisture in the skin<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The anti-oxidative effect of lutein also protects against UV-induced skin damage<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Regarding the subset of carotenoids found in the human macula, previous studies have reported a weak to moderate correlation between MPOD and skin carotenoid (SC) levels measured by resonance Raman spectroscopy (RRS)<sup><xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup>.</p>
              <p id="Par4">The Age-related Eye Disease Study (AREDS) Research Group conducted the first multi-center, randomized trial to verify the prophylactic effect of a supplement containing vitamin C, vitamin E, beta-carotene, and zinc, and demonstrated that this supplement formula reduced the 5-year risk of advanced AMD in persons at risk by 25%<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. A second clinical trial was conducted to investigate the effect of lutein/zeaxanthin instead of beta-carotene<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, because several observational studies demonstrated that higher dietary intake of lutein/zeaxanthin was associated with a decreased risk of advanced AMD<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. According to the AREDS2 study, a prophylactic effect of lutein/zeaxanthin-containing anti-oxidative supplements can be achieved at least for the lowest dietary intake of lutein and zeaxanthin quintile<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. The formula recommended by AREDS2 is: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc oxide 80 mg, and cupric oxide 2 mg. Based on this formula, several commercial products have been released in Japan, although the actual amount of each ingredient may be modified by the manufacturer. For example, commercial products in Japan contain less zinc than the AREDS formula since the maximum allowable amount of zinc in Japan is 30 mg per day, whereas the AREDS formula contains 65 mg of zinc (80 mg of zinc oxide).</p>
              <p id="Par5">In this study, we investigated the change in MPOD and SC levels due to supplement intake of high doses of lutein/zeaxanthin in healthy subjects. This is the first study to show the effects of lutein and zeaxanthin supplementation with vitamin C, vitamin E, zinc, and copper on skin carotenoid levels.</p>
            </sec>
            <sec id="Sec2" sec-type="results">
              <title>Results</title>
              <p id="Par6">This is a prospective, single-arm, open-label study at a single institute (Seirei Hamamatsu General Hospital). Thirty-six healthy volunteers were evaluated between June 2018 and May 2019, and twenty were excluded from enrollment due to incompatibility with the inclusion criteria (Table <xref rid="Tab1" ref-type="table">1</xref>). Six had a spherical equivalent refractive error greater than −6.0 diopter. Thirteen subjects had MPOD exceeding 0.64 at 0.5° eccentricity by heterochromatic flicker photometry (Macular Metrics II Macular Metrics Inc., MA, USA, [abbreviated as HFP-MM II]). One had a choroidal nevus in one eye and MPOD exceeding 0.64 in the other eye. Of the remaining 16 subjects enrolled in the study, 2 were men and 14 were women, ranging in age from 26–57 years (mean age 46.3 ± 7.9). Demographic data of the subjects at baseline and rate of supplement intake during the study period (rate of supplement intake = number of days supplements were taken/total days of the study period) are shown in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion Criteria.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Japanese</td></tr><tr><td>Age: 20–60 years old</td></tr><tr><td>No ocular pathologies detected by slit-lamp biomicroscopy and fundus ophthalmoscopy</td></tr><tr><td>Visual acuity of 0.8* or above at the time of MPOD measurement</td></tr><tr><td>Spherical equivalent refractive error less than −6.0 diopter</td></tr><tr><td>No gastrointestinal diseases that could interfere with dietary absorption</td></tr><tr><td>No diabetes</td></tr><tr><td>No history of lutein/zeaxanthin or co-antioxidants supplement intake</td></tr><tr><td>No allergies to lutein/zeaxanthin</td></tr><tr><td>Not pregnant or breast-feeding</td></tr><tr><td>Pupil diameter of 6.5 mm or more by mydriatic agent.</td></tr><tr><td>MPOD at 0.5° eccentricity measured by MMII is 0.64 or less.</td></tr></tbody></table><table-wrap-foot><p>*The visual acuity was measured using a decimal visual acuity test chart. 0.8 is equivalent to 20/25 of Snellen visual acuity or 0.097 of logMAR.</p><p>MPOD: macular pigment optical density; MMII: Macular Metrics II.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographic data at baseline and rate of supplement intake at the end of the study for all subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Subject</th><th>Sex</th><th>Age (year)</th><th>Body mass index (kg/m<sup>2</sup>)</th><th>Study Eye</th><th>Intraocular pressure (mmHg)</th><th>Spherical equivalent refractive error (Diopter)</th><th>Central macular thickness by OCT (μm)</th><th>Rate of supplement taking (%)</th></tr></thead><tbody><tr><td>1</td><td>female</td><td>49</td><td>21.5</td><td>Right</td><td>11.7</td><td>−3.25</td><td>246</td><td>94</td></tr><tr><td>2</td><td>female</td><td>48</td><td>29.0</td><td>Right</td><td>19.0</td><td>0.00</td><td>283</td><td>100</td></tr><tr><td>3</td><td>female</td><td>40</td><td>22.9</td><td>Right</td><td>18.7</td><td>−5.00</td><td>239</td><td>96</td></tr><tr><td>4</td><td>female</td><td>54</td><td>20.3</td><td>Left</td><td>13.3</td><td>−3.00</td><td>257</td><td>92</td></tr><tr><td>5</td><td>female</td><td>42</td><td>21.1</td><td>Left</td><td>12.3</td><td>−4.75</td><td>263</td><td>100</td></tr><tr><td>6</td><td>female</td><td>41</td><td>20.8</td><td>Right</td><td>18.3</td><td>0.00</td><td>272</td><td>98</td></tr><tr><td>7</td><td>female</td><td>44</td><td>21.1</td><td>Left</td><td>11.7</td><td>0.00</td><td>263</td><td>99</td></tr><tr><td>8</td><td>female</td><td>57</td><td>28.1</td><td>Right</td><td>17.7</td><td>−0.75</td><td>254</td><td>97</td></tr><tr><td>9</td><td>female</td><td>51</td><td>19.7</td><td>Right</td><td>17.0</td><td>−1.00</td><td>265</td><td>100</td></tr><tr><td>10</td><td>female</td><td>51</td><td>19.8</td><td>Left</td><td>12.0</td><td>−1.00</td><td>264</td><td>91</td></tr><tr><td>11</td><td>female</td><td>44</td><td>16.8</td><td>Left</td><td>14.3</td><td>−2.50</td><td>264</td><td>96</td></tr><tr><td>12</td><td>male</td><td>38</td><td>22.6</td><td>Right</td><td>16.3</td><td>−3.50</td><td>253</td><td>88</td></tr><tr><td>13</td><td>female</td><td>26</td><td>23.5</td><td>Left</td><td>18.3</td><td>−0.50</td><td>258</td><td>100</td></tr><tr><td>14</td><td>female</td><td>53</td><td>21.2</td><td>Left</td><td>10.0</td><td>−1.50</td><td>246</td><td>99</td></tr><tr><td>15</td><td>male</td><td>46</td><td>26.1</td><td>Left</td><td>20.3</td><td>−3.75</td><td>283</td><td>94</td></tr><tr><td>16</td><td>female</td><td>56</td><td>19.6</td><td>Left</td><td>14.0</td><td>−0.75</td><td>239</td><td>100</td></tr></tbody></table><table-wrap-foot><p>Rate of supplement taking = actual no. of days of intake/total no. of days of the study period.</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec3">
                <title>Change in visual function and OCT imaging</title>
                <p id="Par7">Best corrected far and near decimal visual acuities at baseline were 1.2 and 1.0 in all subjects, and no change in visual acuity throughout the study period was observed in any subject. Mean retinal thickness at 1-mm diameter central area (central retinal thickness, CRT) measured by optical coherence tomography (OCT) of each subject at baseline was between 239–283 μm. Mean CRT values ± standard deviation (SD) for all subjects at baseline, week 4, week 8, week 12, and week 16 were 259.2 ± 10.5, 258.4 ± 11.4, 259.2 ± 12.3, 259.9 ± 13.0, and 259.1 ± 11.1 μm, respectively. No significant differences in CRT were observed at each time period for all subjects (<italic>p</italic> = 0.661, two-way factorial ANOVA). Baseline contrast sensitivity (C_AULCSF [the area under the log contrast sensitivity function]) was from 1.61 to 1.84, and glare disability (G_AULCSF) was from 0.85 to 1.49. Mean C_AULCSF at baseline, week 8, and week 16 were 1.74 ± 0.07, 1.76 ± 0.11 and 1.76 ± 0.08, respectively. Mean G_AULCSF at baseline, week 8, and week 16 were 1.25 ± 0.15, 1.26 ± 0.12, and 1.28 ± 0.13, respectively. No significant differences in C_AULCSF and G_AULCSF were observed at each time period for all subjects (<italic>p</italic> = 0.567, 0.577, two-way factorial ANOVA).</p>
              </sec>
              <sec id="Sec4">
                <title>Changes in MPOD levels</title>
                <p id="Par8">MPOD levels of the study eye were measured using two different methods at baseline and 4, 8, 12, and 16 weeks after starting supplement intake. MPOD levels measured by HFP-MMII at baseline varied between subjects from 0.31–1.10 at 0.25° eccentricity and 0.27–0.63 at 0.5° eccentricity. Mean values at 0.25° and 0.5° eccentricities were 0.62 ± 0.20 and 0.49 ± 0.11, respectively. Mean baseline MPOD levels and mean MPOD levels obtained for all subjects at time points 4,8,12, and 16 weeks are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. No significant differences in mean MPOD at either eccentricity at each time period (<italic>p</italic> = 0458, 0.056, two-way factorial ANOVA) were observed.<fig id="Fig1"><label>Figure 1</label><caption><p>Changes in mean MPOD measured by Macular Metrics II. No significant change in mean macular pigment optical density (MPOD) at both eccentricities at each time period (0.25°, <italic>p</italic> = 0.458, 0.5°, <italic>p</italic> = 0.056, two-way factorial ANOVA). Blue: 0.25°; Red: 0.5°. Bar represents standard deviation.</p></caption><graphic xlink:href="41598_2020_66962_Fig1_HTML" id="d30e966"/></fig></p>
                <p id="Par9">Local MPOD of each subject measured by two-wavelength autofluorescence imaging, AFI-SP (autofluorescence imaging, a prototype SPECTRALIS MultiColor platform with MPOD module [Heidelberg Engineering, Heidelberg, Germany]) at 0.25°, 0.5°, 1°, and 2° eccentricities at baseline were 0.28–0.73, 0.19–0.64, 0.20–0.60, and 0.05–0.28, respectively. Mean values at 0.25°, 0.5°, 1°, and 2° eccentricities were 0.49 ± 0.12, 0.46 ± 0.12, 0.45 ± 0.10, and 0.19 ± 0.06, respectively. Corresponding mean MPOD levels obtained for all subjects at baseline and time points 4,8,12, and 16 weeks are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. No significant difference in local MPOD levels for each subject during the test period were observed again for the four eccentricities (<italic>p</italic> = 0.801, 0.310, 0.205, 0.534, two-way factorial ANOVA). Total MPOV for each subject at baseline ranged from 4527 to 16535. Mean values at baseline, week 4, week 8, week 12 and week 16 were 12097 ± 3192, 12203 ± 3476, 12585 ± 3111, 13093 ± 3371, and 13408 ± 3521, respectively. Corresponding mean total MPOV levels obtained for all subjects at baseline and time points 4,8,12, and 16 weeks are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The mean total MPOV at week 4 was not significantly higher than at baseline. However, those at week 8, 12, and 16 were significantly higher than at baseline (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA, baseline/week 4, <italic>p</italic> = 0.641, baseline/week 8, <italic>p</italic> = 0.034; baseline/week12, <italic>p</italic> &lt; 0.001; baseline/week 16, <italic>p</italic> &lt; 0.001, post-hoc with LSD). The increase in total MPOV at week 16 for each subject (i.e. (total MPOV at week 16 – total MPOV at baseline) / total MPOV at baseline) ranged between 3–27%, with a mean of 11%.<fig id="Fig2"><label>Figure 2</label><caption><p>Changes in mean local MPOD measured by SPECTRALIS. No significant change in mean MPOD at all four eccentricities during the study period. Blue: 0.25°; Red: 0.5°; Green: 1°, Purple: 2°. Bar represents standard deviation.</p></caption><graphic xlink:href="41598_2020_66962_Fig2_HTML" id="d30e1002"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>Change in mean total MPOV measured by SPECTRALIS. Mean total macular pigment optical density volume (MPOV) at week 8, 12, and 16 are significantly higher than that at baseline (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA, baseline/week 8, <italic>p</italic> = 0.034; baseline/week12, <italic>p</italic> &lt; 0.0001; baseline/week 16, <italic>p</italic> &lt; 0.0001, post-hoc with LSD). Bar represents standard deviation.</p></caption><graphic xlink:href="41598_2020_66962_Fig3_HTML" id="d30e1023"/></fig></p>
                <p id="Par10">A significant negative correlation between body mass index (BMI) at baseline and increase in local MPOD levels at week 16, excluding local MPOD at 0.5°, was observed (Table <xref rid="Tab3" ref-type="table">3</xref>). The correlation between BMI and increased local MPOD at 0.5° was marginal, however. Subjects with higher BMI showed a smaller increase of local MPOD levels than subjects with lower BMI. No significant correlation between BMI and the increase of total MPOV at week 16 was observed. However, when BMIs were divided into two groups, one with BMI lower than 25 kg/m<sup>2</sup> (n = 13), and the other with BMI 25 kg/m<sup>2</sup> and higher that is defined as obese in Japanese (n = 3), a significant difference in the increase of local MPOD at 0.25°, 1°, and 2° and total MPOV at week 16 was observed (Table <xref rid="Tab4" ref-type="table">4</xref>). Percentage increases were higher in the lower BMI group. Local MPOD and total MPOV did not increase in the higher BMI group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Correlation between body mass index and rate of increase for local MPOD or total MPOV at week 16.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Pearson’s correlation coefficient</th><th><italic>p</italic></th></tr></thead><tbody><tr><td><bold>MPOD at 0.25°</bold></td><td><bold>−0.629</bold></td><td><bold>0.009</bold></td></tr><tr><td>MPOD at 0.5°</td><td>−0.474</td><td>0.064</td></tr><tr><td><bold>MPOD at 1°</bold></td><td><bold>−0.622</bold></td><td><bold>0.010</bold></td></tr><tr><td><bold>MPOD at 2°</bold></td><td><bold>−0.567</bold></td><td><bold>0.022</bold></td></tr><tr><td>Total MPOV</td><td>−0.338</td><td>0.200</td></tr></tbody></table><table-wrap-foot><p>MPOD: macular pigment optical density; MPOV macular pigment optical volume.</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>The rate of increase for local MPOD and total MPOV at week 16 in subjects with BMI* less than 25 and subjects with BMI 25 and more.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>BMI less than 25(n = 13)</th><th>BMI 25 and more(n = 3)</th><th><italic>p</italic> (t-test)</th></tr></thead><tbody><tr><td>MPOD at 0.25°</td><td><bold>0.005</bold></td><td><bold>−0.10</bold></td><td><bold>0.001</bold></td></tr><tr><td>MPOD at 0.5°</td><td>0.26</td><td>−0.07</td><td>0.344</td></tr><tr><td>MPOD at 1°</td><td><bold>0.04</bold></td><td><bold>−0.05</bold></td><td><bold>0.001</bold></td></tr><tr><td>MPOD at 2°</td><td><bold>0.04</bold></td><td><bold>−0.07</bold></td><td><bold>0.001</bold></td></tr><tr><td>Total MPOV</td><td><bold>0.13</bold></td><td><bold>−0.12</bold></td><td><bold>0.007</bold></td></tr></tbody></table><table-wrap-foot><p>MPOD: macular pigment optical density; MPOV macular pigment optical volume; BMI: body mass index.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec5">
                <title>Changes in skin carotenoid levels</title>
                <p id="Par11">SC levels of each subject at baseline ranged from 37–483. Mean SC levels of all subjects at baseline, week 4, week 8, week 12, and week 16 were 277 ± 98, 337 ± 137, 380 ± 144, 402 ± 128, and 423 ± 172. The change in mean SC levels of all subjects is shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Mean SC levels at week 4, 8, 12, and 16 were significantly higher than that at baseline (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA, baseline/week 4, <italic>p</italic> = 0.010; baseline/week 8, <italic>p</italic> &lt; 0.0001; baseline/week12, <italic>p</italic> &lt; 0.0001; baseline/week 16, <italic>p</italic> &lt; 0.0001, post-hoc with LSD). Percentage increases in SC levels at week 16 of each subject except for one, (SC level at week 16 – SC level at baseline) / SC level at baseline) ranged between 16–114%, with a mean of 48%. For an exceptional subject, discussed in the discussion section who scored a noticeably low SC value at baseline, the increase in SC amounted to 616%. No significant correlation between BMI at baseline and the increase in SC levels at week 16 was observed (Pearson’s coefficient: 0.126, <italic>p</italic> = 0.641). In addition, no significant difference in the increased SC levels at week 16 between subjects in the low and high BMI groups was observed (<italic>p</italic> = 0.775, t-test).<fig id="Fig4"><label>Figure 4</label><caption><p>Change in mean skin carotenoid levels of all subjects.Mean SC levels at week 4, 8, 12, and 16 are significantly higher than that at baseline (<italic>p</italic> &lt; 0.0001, two-way factorial ANOVA, baseline/week 4, <italic>p</italic> = 0.010; baseline/week 8, <italic>p</italic> &lt; 0.0001; baseline/week12, <italic>p</italic> &lt; 0.0001; baseline/week 16, <italic>p</italic> &lt; 0.0001, post-hoc with LSD). Bar represents standard deviation.</p></caption><graphic xlink:href="41598_2020_66962_Fig4_HTML" id="d30e1282"/></fig></p>
              </sec>
              <sec id="Sec6">
                <title>Mutual correlations</title>
                <sec id="Sec7">
                  <title>Correlation between contrast/glare sensitivity and MPOD levels / skin carotenoid levels at baseline</title>
                  <p id="Par12">No significant correlation between C_AULCSF at baseline and SC levels, local MPOD levels, or MPOD volume were observed (Table <xref rid="Tab5" ref-type="table">5</xref>). In addition, there were no significant correlations between G_AULCSF at baseline and SC levels, local MPOD levels, except for local MPOD levels at 0.98°, or MPOD volume (Table <xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Correlation coefficient between contrast/glare sensitivity and MPOD levels/skin carotenoid levels at baseline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Contrast/glare sensitivity</th><th>MPOD/skin carotenoid levels</th><th>Pearson’s correlation coefficient</th><th><italic>p</italic></th></tr></thead><tbody><tr><td rowspan="6">C_AULCSF</td><td>MPOD at 0.25°</td><td>−0.090</td><td>0.741</td></tr><tr><td>MPOD at 0.5°</td><td>−0.345</td><td>0.190</td></tr><tr><td>MPOD at 1°</td><td>−0.372</td><td>0.155</td></tr><tr><td>MPOD at 2°</td><td>−0.243</td><td>0.364</td></tr><tr><td>Total MPOV</td><td>−0.241</td><td>0.368</td></tr><tr><td>Skin carotenoid levels</td><td>0.165</td><td>0.541</td></tr><tr><td rowspan="6">G_AULCSF</td><td>MPOD at 0.25°</td><td>−0.310</td><td>0.243</td></tr><tr><td>MPOD at 0.5°</td><td>−0.348</td><td>0.186</td></tr><tr><td>MPOD at 1°</td><td><bold>−0.504</bold></td><td><bold>0.046</bold></td></tr><tr><td>MPOD at 2°</td><td>−0.367</td><td>0.162</td></tr><tr><td>Total MPOV</td><td>−0.269</td><td>0.314</td></tr><tr><td>Skin carotenoid levels</td><td>0.121</td><td>0.655</td></tr></tbody></table><table-wrap-foot><p>C_AULCSF: contrast the area under the log contrast sensitivity function; G_AULCSF: glare the area under the log contrast sensitivity function; MPOD: macular pigment optical density; MPOV macular pigment optical volume.</p></table-wrap-foot></table-wrap></p>
                </sec>
                <sec id="Sec8">
                  <title>Correlation between MPOD levels and skin carotenoid levels</title>
                  <p id="Par13">No significant correlation between SC levels and local MPOD levels or total MPOV at baseline were observed (Table <xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab6"><label>Table 6</label><caption><p>Correlation between MPOD levels and skin carotenoid levels at baseline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Pearson’s correlation coefficient</th><th><italic>p</italic></th></tr></thead><tbody><tr><td>MPOD at 0.25°</td><td>−0.120</td><td>0.658</td></tr><tr><td>MPOD at 0.5°</td><td>−0.062</td><td>0.819</td></tr><tr><td>MPOD at 1°</td><td>−0.204</td><td>0.449</td></tr><tr><td>MPOD at 2°</td><td>−0.008</td><td>0.976</td></tr><tr><td>total MPOV</td><td>0.091</td><td>0.738</td></tr></tbody></table><table-wrap-foot><p>MPOD: macular pigment optical density; MPOV macular pigment optical volume.</p></table-wrap-foot></table-wrap></p>
                </sec>
                <sec id="Sec9">
                  <title>Safety</title>
                  <p id="Par14">All subjects completed the study without serious adverse events. Seven subjects reported changes in general condition for some days during the study period (Table <xref rid="Tab7" ref-type="table">7</xref>). No subjects consulted a doctor due to the changes, but three took anti-inflammatory and/or analgesic medicine for the common cold and/or a headache.<table-wrap id="Tab7"><label>Table 7</label><caption><p>Change in general condition in each subject.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Subject No.</th><th>Number of the days change in general condition was felt</th><th>Symptom</th><th>Self-estimated reasons</th></tr></thead><tbody><tr><td>1</td><td>1</td><td>Headache</td><td>Shoulder stiffness</td></tr><tr><td/><td>1</td><td>Menstrual pain</td><td/></tr><tr><td>2</td><td>0</td><td/><td/></tr><tr><td>3</td><td>0</td><td/><td/></tr><tr><td>4</td><td>0</td><td/><td/></tr><tr><td>5</td><td>1</td><td>Sneezing, runny nose</td><td>Common cold</td></tr><tr><td>6</td><td>0</td><td/><td/></tr><tr><td>7</td><td>1</td><td>Headache</td><td>Shoulder stiffness</td></tr><tr><td>8*</td><td>4</td><td>Sore throat</td><td>Common cold</td></tr><tr><td>9</td><td>0</td><td/><td/></tr><tr><td>10</td><td>0</td><td/><td/></tr><tr><td>11</td><td>1</td><td>Pain at the base of a finger</td><td>Unknown</td></tr><tr><td>12*</td><td>1</td><td>Stomach ache</td><td>Unknown</td></tr><tr><td/><td>4</td><td>Sneeze, runny nose, fever</td><td>Common cold</td></tr><tr><td>13*</td><td>2</td><td>headache</td><td>Unknown</td></tr><tr><td/><td>4</td><td>Stomach ache, nausea</td><td>Stress</td></tr><tr><td>14</td><td>0</td><td/><td/></tr><tr><td>15</td><td>0</td><td/><td/></tr><tr><td>16</td><td>0</td><td/><td/></tr></tbody></table><table-wrap-foot><p>*Subjects who declared taking medicine.</p></table-wrap-foot></table-wrap></p>
                  <p id="Par15">Changes in blood tests between baseline and week 16 are shown in Table <xref rid="Tab8" ref-type="table">8</xref>. Statistically significant changes were observed in platelet, total protein, total cholesterol, low-density lipoprotein (LDL)-cholesterol, creatinine, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels. However, no clinical significance was determined for platelet, total protein, creatinine, alkaline phosphatase, alanine aminotransferase, as values at week 16 were within standard levels or had improved over baseline. An increase in total cholesterol was observed in 12 subjects at week 16, and four of them showed an increase from a normal range to values exceeding the upper limit. In contrast, of the four subjects who had total cholesterol values exceeding the normal limit at baseline, a decrease was observed in three of them at week 16. An increase in LDL-cholesterol was observed in 11 subjects, of which an increase from normal range to values exceeding the upper limit was observed in four of them.<table-wrap id="Tab8"><label>Table 8</label><caption><p>Mean values of blood tests at baseline and week 16.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Baseline</th><th>Week 16</th><th><italic>p</italic> (t-test)</th></tr></thead><tbody><tr><td>Red blood cells (RBC)/μL</td><td>456 × 10<sup>4</sup></td><td>457 × 10<sup>4</sup></td><td>0.911</td></tr><tr><td>White blood cells (WBC)/μL</td><td>6,625</td><td>6,313</td><td>0.288</td></tr><tr><td>Platelets (PLT)/μL</td><td><bold>31.2</bold> × 10<sup>4</sup></td><td><bold>29.3</bold> × 10<sup>4</sup></td><td><bold>0.005</bold></td></tr><tr><td>Hemoglobin (Hb) (g/dL)</td><td>13.5</td><td>13.5</td><td>0.929</td></tr><tr><td>Hematocrit (Ht) (%)</td><td>41.5</td><td>41.7</td><td>0.451</td></tr><tr><td>MCV (fL)</td><td>90.8</td><td>91.5</td><td>0.029</td></tr><tr><td>MCH (pg)</td><td>29.5</td><td>29.5</td><td>0.731</td></tr><tr><td>MCHC (g/dL)</td><td>32.4</td><td>32.2</td><td>0.665</td></tr><tr><td>Total protein (TP) (g/dL)</td><td><bold>7.4</bold></td><td><bold>7.3</bold></td><td><bold>0.020</bold></td></tr><tr><td>Total cholesterol (TC) (mg/dL)</td><td><bold>212</bold></td><td><bold>227</bold></td><td><bold>0.011</bold></td></tr><tr><td>HDL-cholesterol (mg/dL)</td><td>74</td><td>76</td><td>0.225</td></tr><tr><td>LDL-cholesterol (mg/dL)</td><td><bold>124</bold></td><td><bold>135</bold></td><td><bold>0.012</bold></td></tr><tr><td>Albumin(Alb) (g/dL)</td><td>4.5</td><td>4.4</td><td>0.590</td></tr><tr><td>Total bilirubin (T-Bil) (mg/dL)</td><td>0.45</td><td>0.56</td><td>0.006</td></tr><tr><td>Triglyceride (TG) (mg/dL)</td><td>102</td><td>95</td><td>0.366</td></tr><tr><td>Urea nitrogen (mg/dL)</td><td>13.2</td><td>14.0</td><td>0.120</td></tr><tr><td>Creatinine (Cr) (mg/dL)</td><td><bold>0.66</bold></td><td><bold>0.63</bold></td><td><bold>0.015</bold></td></tr><tr><td>Alkaline phosphatase (ALP) (U/L)</td><td><bold>194</bold></td><td><bold>211</bold></td><td><bold>0.016</bold></td></tr><tr><td>Aspartate aminotransferase (AST) (U/L)</td><td><bold>17.4</bold></td><td><bold>20.5</bold></td><td><bold>0.006</bold></td></tr><tr><td>Alanine aminotransferase (ALT) (U/L)</td><td><bold>15.7</bold></td><td><bold>20.3</bold></td><td><bold>0.043</bold></td></tr><tr><td>gamma-glutamyl transpeptidase (γ-GT) (U/L)</td><td>21</td><td>26</td><td>0.130</td></tr><tr><td>Lactic dehydrogenase (LD) (U/L)</td><td>169</td><td>168</td><td>0.766</td></tr><tr><td>Glucose (mg/dL)</td><td>94.9</td><td>98.5</td><td>0.141</td></tr></tbody></table></table-wrap></p>
                  <p id="Par16">All urine qualitative tests for pH, protein, glucose, urobilinogen, ketone body were negative for all subjects at baseline and week 16. Urine blood tests were positive for 6 female subjects at baseline, of which two were positive at week 16.</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec10" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par17">Mean total MPOV significantly increased at 8 weeks after the start of supplement intake and continued to increase until the end of supplement intake at week 16. Mean SC levels also increased at 4 weeks and continued to increase until week 16. A significantly higher increase in local MPODs and total MPOV at week 16 was observed in subjects with BMI less than 25 kg/m<sup>2</sup> compared to subjects with BMI 25 kg/m<sup>2</sup> and more. All subjects completed the study without serious adverse events. These results demonstrated the effectiveness of the present supplement on the eye and skin.</p>
              <p id="Par18">In this study, only those subjects were selected who had MPOD levels of 0.64 and lower at 0.5° eccentricity. The rationale for this selection is the avoidance of subjects with already saturated macular pigment, who would not be able to respond with a further increase upon supplementation<sup><xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR31">31</xref></sup>. The value of 0.64 was chosen based on our previous study<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. HFP-MM II was used for screening because it can be carried out without mydriasis. According to our previous study, MPOD hardly increased in myopic subjects in response to supplementation<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Consequently, subjects with myopia of −6.0D or higher were excluded as well.</p>
              <p id="Par19">A significant increase in MPOD levels measured by heterochromatic flicker photometry at four weeks and later has already been reported in many previous studies<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR35">35</xref></sup>. Concerning the time at which a significant increase was observed, one study used a high dose <italic>meso</italic>-zeaxanthin supplement<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and reported a rapid increase of MPOD just two weeks later. In contrast, a relatively slow increase of MPOD (significant increase observed only at 12 weeks and after) was reported for a dietary investigation study with spinach and corn<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. One study, using the same lutein product as in this study (20 mg lutein and 4 mg zeaxanthin) reported a significant increase at 8 weeks and after<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, which is in agreement with this study. Concerning the increase in amount of MPOD level, previous studies reported it increases between 4–39%<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR36">36</xref></sup>. Mean increase of total MPOV at week 16 in this study was 11%. Speed and achievable percentage MPOD increases are affected by various factors, such as the type of lutein (i.e., free versus esterified), the amount of zeaxanthin and <italic>meso</italic>-zeaxanthin, the matrix of the formulation, and subject characteristics (e.g., age, sex, MPOD at baseline, smoking history and BMI). When interpreting the results, it is important to consider the respective method used to measure MPOD and evaluated parameters such as local MPOD or MPOV. Therefore, comparison of these results with previous studies is difficult. However, the MPOD increase in this study was relatively slow and the percentage increase was moderate compared to previous studies. Possible reasons for this are as follows. The mean total MPOV at baseline of the subjects in this study was higher than in previous studies. Total MPOV at baseline in the study by G-Gomez was 5094, with a reference point at 7°, and in the study by Nolan, et al., it was 6593, with a reference point at 8° <sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Mean baseline total MPOV in this study was 12097, with a reference point at 9°. This value was converted to 8138 with a reference point at 7°, when we re-calculated MPOV with this reference point. While subjects with a relatively low MPOD levels were selected, a potentially still high MPOD at baseline might be a reason for the moderate increase. Other possible reasons are subject characteristics other than baseline MPOD and unknown interactions with other nutrients.</p>
              <p id="Par20">The ability of the supplement to increase MPOD was influenced by BMI in this study. The increase in total MPOV at week 16 was significantly higher in subjects with BMI less than 25 kg/m<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> than in subjects with BMI 25 kg/m<sup>2</sup> and higher (Table <xref rid="Tab4" ref-type="table">4</xref>). Interestingly, local MPOD levels and total MPOV did not increase with supplement intake in subjects with BMI 25 kg/m<sup>2</sup> and more. An increase of 5% or more in total MPOV was observed in 12 subjects (subjects no. 1, 3, 4, 5, 6, 7, 9, 10, 12, 13, 14, 16 in Table <xref rid="Tab3" ref-type="table">3</xref>) and was not observed in 4 subjects. Of the four subjects whose total MPOV did not increase, three (subject no. 2, 8, 15 in Table <xref rid="Tab2" ref-type="table">2</xref>) had the highest BMI in this study (29.0, 28.1, 26.1) and one subject (subject no. 11) had the lowest BMI (16.8 kg/m<sup>2</sup>). High BMI was reported to be a factor in low MPOD levels in previous studies<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. Adipose tissue and the retina competed for lutein<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. A higher amount of body fat provides a larger “sink” for lutein, which makes less lutein available for other tissues. The subject with the lowest BMI (162 cm height, 44 kg body weight) may have some form of diet malabsorption.</p>
              <p id="Par21">In this study, the effect of supplement intake was observed for total MPOV but not for local MPOD levels. The reason for this discrepancy is thought to be as follows. The MP distribution is not symmetrical and can be roughly divided into four major patterns<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. From this, local MPOD levels could possibly vary between eyes, even in cases where the total amount of MP is the same. The local MPOD level at discrete eccentricities does not always reflect the total amount of MP at the macula. In contrast, total MPOV provides an overall description of MP across the macula. Total MPOV by AFI-SP was reported to be more appropriate to evaluate the effect of supplementation, and total MPOV could be the standard value to assess MP<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
              <p id="Par22">In our previous study<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, the average SC level was 32% higher in subjects taking lutein supplements relative to non-supplementing subjects. The possibility to increase SC levels by beta-carotene, lycopene, and vegetable juice consumption was demonstrated by interventional studies<sup><xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR46">46</xref></sup>. However, no interventional study using lutein/zeaxanthin supplements has been performed to date. This study directly confirmed the effect of lutein/zeaxanthin supplementation on SC levels for the first time. It has been reported that lycopene and beta-carotene levels are predominant in skin, and the amount of lutein and zeaxanthin is much less than carotene<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. However, a more recent study found a higher level, roughly 15%, amount of lutein and zeaxanthin in heel skin samples<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, and the present results were consistent with this finding. Our previous study<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> showed that BMI was a factor for a significant difference in SC levels, but in this study, no significant difference was observed. A possible reason for this discrepancy is the small number of subjects in this study.</p>
              <p id="Par23">A significant increase in SC levels at week 4 was observed, while in contrast, a significant increase in MPOV was observed only at week 8. The reason for this time lag is considered to be as follows. SC levels are reported to reflect serum concentration of the carotenoids<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR53">53</xref></sup>. Supplements induce a quick increase in serum lutein and zeaxanthin concentrations that reflect the increase in SC levels. In contrast, MP has been reported to accumulate gradually in the retina, so more time must elapse in order to detect a significant change. In other words, after taking supplements, SC levels increase first, while MP increases later.</p>
              <p id="Par24">The SC value in one subject (No.12 in Table <xref rid="Tab2" ref-type="table">2</xref>) at baseline was very low. When we analyzed the SC changes without the results for this outlier subject, an increase in SC levels was still observed depending on the time period (<italic>p</italic> &lt; 0.0001, two-way repeated ANOVA). The reason for the lack of significant improvement in visual functions and lack of significant correlation between contrast and/or glare sensitivity and MPOD levels/SC levels was considered to be due to good visual functions already present at baseline in healthy subjects.</p>
              <p id="Par25">Supplement intake compliance varied from 88–100%. The low supplement intake rates were due to subject forgetfulness, but no one refused to take the supplement due to change in general condition. Lutein intake of up to 1 mg/kg body weight (20 to 40 mg/day) and zeaxanthin intake of up to 0.75 mg/kg body weight are considered safe<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. However, one report<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> noted that overdose lutein resulted in yellow deposits in the retina; hence, caution is needed to avoid excessive intake of lutein. From the results of blood tests, no serious adverse effects were observed, but increase in total cholesterol and LDL-cholesterol was noted. Increase in total cholesterol at week 16 was observed in 12 subjects, of which increase from the normal range to exceeding the upper limit was observed in 4 subjects. Increase in LDL-cholesterol was observed in 11 subjects, of which increase from the normal range to exceeding the upper limit was observed in 4 subjects. The present supplement contained sunflower oil, safflower oil, fatty acid ester, and glycerol fatty acid ester. These fatty acids may influence total cholesterol and LDL-cholesterol levels. However, for three of four subjects who had total cholesterol values of higher than the normal limit at baseline, a decrease in cholesterol levels to the normal range at week 16 was observed. Cholesterol levels are assumed to be highly affected by daily diet, which was not examined in this study. Consideration of the effect of cholesterol due to the supplements is needed in the future.</p>
              <p id="Par26">From the results of this study, the effectiveness of supplements containing 20 mg of lutein and 4 mg of zeaxanthin combined with co-antioxidants on MPOV and SC levels without any serious adverse event could be demonstrated in subjects with relatively low MPOD levels at baseline. Limitations of this study included its study design as a single arm without a control group and the small number of subjects. A lack of assessment of dietary intake of lutein and zeaxanthin during the study period was another shortcoming.</p>
            </sec>
            <sec id="Sec11">
              <title>Methods</title>
              <sec id="Sec12">
                <title>Subjects</title>
                <p id="Par27">Sample size was based on our previous study<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. In this study, mean MPOD was measured by the same method as the present study before and after intake of a 10 mg lutein supplement, with values of 0.62 and 0.72, respectively, with a standard deviation (SD) of 0.06. Increase was 16% which was comparable to that of other studies<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. When α error is set at 0.05 and power at 0.8, the number of subjects with significant results in a comparative study was 14. Similarly, we set number of our subjects at 16. Self-selected recruitment of subjects was facilitated by intranet information of Seirei Hamamatsu General Hospital and by word of mouth. Measurements of far and near visual acuities and intraocular pressure, observation by slit-lamp biomicroscopy and fundus ophthalmoscopy, and OCT were performed before enrollment in order to assess the inclusion criteria. MPOD was measured using heterochromatic flicker photometry (HFP-MM II) with a reference point of 7° eccentricity, and subjects with a MPOD at 0.5° eccentricity of 0.64 or less were enrolled. Subjects with a MPOD greater than 0.64 were excluded. Details of the inclusion criteria are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. When both eyes met the inclusion criteria, the targeted eye was determined based on subject preference, and the following examinations were performed only on the targeted eye.</p>
                <p id="Par28">The study was approved by the institutional review board of Seirei Hamamatsu General Hospital (No.2965) and registered as No. UMIN000031870. All subjects provided a written informed consent form that complied with the tenets of the Declaration of Helsinki.</p>
              </sec>
              <sec id="Sec13">
                <title>Assessment of visual functions and OCT imaging</title>
                <p id="Par29">Subjects were measured for far and near visual acuities using a decimal visual acuity test chart, and given a contrast and glare sensitivity test using a contrast glare-tester (Model CGT-1000, TAKAGI, Nagano, Japan), at baseline, and 8 and 16 weeks after starting supplement intake. Contrast threshold values were assessed at six visual angles (sizes) of the target (6.3, 4.0, 2.5, 1.6, 1.0, 0.7 degrees) under mesopic (10 candelas per square meter) and glare (10,000 candelas per square meter) conditions, and the area under the log contrast sensitivity function (AULCSF) was used to evaluate contrast sensitivity in the normal setting (C_AULCSF) and in the presence of glare light (G_AULCSF). OCT imaging was obtained at baseline and 4, 8, 12, and 16 weeks after starting supplement intake. Mean retinal thickness at 1-mm diameter central area (central retinal thickness, CRT) was obtained using SPECTRALIS software by volume scan with 20° × 15° in the 19 B-scan mode.</p>
              </sec>
              <sec id="Sec14">
                <title>Measurement of macular pigment optical density</title>
                <p id="Par30">MPOD levels of the study eye were measured using two different methods at baseline and 4, 8, 12, and 16 weeks after starting supplement intake. First, MPOD was measured by HFP-MM II without mydriasis. MPOD values at 0.25° and 0.5°eccentricities with a reference point of 7° eccentricity were evaluated. Then, the pupil was dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide, and MPOD was measured by two-wavelength autofluorescence imaging, AFI-SP. Basic functionality and handling of this instrument have been previously described<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Measurements are carried out with alternating blue and green laser light sources which are raster scanned over the retina for about 30 seconds. In contrast to earlier digital camera-based instruments that captured autofluorescence images with a single blue or green flash, AFI-SP uses a scanning laser technique that does not require pre-bleaching of photopigments. Optical densities at 0.25°, 0.5°, 1°, and 2°eccentricities (local MPODs), and total optical density volume within 9° eccentricity (total MPOV) were used for analyses. 9° eccentricity was set as a reference point. The local MPOD level is the average along a concentric circle at selected eccentricities, and total MPOV is the total of MPODs within 9° eccentricity. Total MPOV correlated to MPOD at each eccentricity and has been proposed as the preferred metric for the assessment of macular pigment<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
              </sec>
              <sec id="Sec15">
                <title>Measurement of skin carotenoid levels</title>
                <p id="Par31">Pressure-mediated reflection spectroscopy (VEGGIE METER, Longevity Link Corporation, Salt Lake City, Utah) was used to measure SC levels. Basic functions of this device have been previously described<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. VEGGIE METER has been validated by comparing it to skin resonance Raman spectroscopy which has high specificity for carotenoid molecules<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Calibration was performed with the provided dark and white reference materials prior to daily skin measurements. Subjects placed their left middle finger into the device’s finger cradle and pressed their fingertip against the convex contact lens surface with the assistance of a spring-loaded lid. Slight pressure was applied to the fingertip to reduce blood perfusion of the measured tissue, which prevents highly blood with its high visible light absorbance from interfering with measurement of skin carotenoid levels. SC index was determined as the average of three consecutive measurements.</p>
              </sec>
              <sec id="Sec16">
                <title>Supplement</title>
                <p id="Par32">Commercially available gelatin soft capsule supplements containing lutein/zeaxanthin (OPTIADE ML, WAKAMOTO Pharmaceutical Co., Ltd, Tokyo, Japan) were used. The subjects orally took three capsules after a meal with water once a day for 16 weeks. Contents of three capsules were: lutein 20 mg (6.7 mg per capsule), zeaxanthin (3R,3′R-zeaxanthin and 3R, 35–45%, 3′S; meso-zeaxanthin, 55–65%) 4 mg (1.3 mg per capsule), vitamin C 408 mg, vitamin E 242.3 mg, zinc 30 mg, copper 1.5 mg. Lutein and zeaxanthin material used in this supplement was Lutemax 2020 (OmniActive Health Technologies Ltd., Mumbai, India). The carotenoids were suspended in a mixture of sunflower oil, safflower oil, beeswax, fatty acid ester, and glycerol ester. Soft capsules were made from porcine gelatin and glycerol. Table <xref rid="Tab9" ref-type="table">9</xref> shows the nutritional ingredients for one day (3 capsules). Supplements were provided to each subject every four weeks. The subjects were requested to record the time the supplement was taken in a notebook each day, and any remaining capsules were collected so that the study coordinator could confirm the compliance of the subjects.<table-wrap id="Tab9"><label>Table 9</label><caption><p>Nutritional ingredients of the supplements for one day (3 capsules).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Nutritional ingredients</th><th/><th/></tr></thead><tbody><tr><td>Energy</td><td>(kcal)</td><td>10.7</td></tr><tr><td>Protein</td><td>(g)</td><td>0.59</td></tr><tr><td>Fat</td><td>(g)</td><td>0.64</td></tr><tr><td>Carbohydrate</td><td>(g)</td><td>0.64</td></tr><tr><td>Sodium</td><td>(mg)</td><td>0.0014</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec17">
                <title>Assessment of the safety of the supplement</title>
                <p id="Par33">Subjects were asked about their general condition and past history of illness, and measurements of height and body weight were taken at baseline. Subjects were asked to record any change in general condition, details of any medicine taken (name and amount of the drug), and any changes in their lifestyle in the notebook every day. Fasting blood and urine tests were performed at baseline and after 16 weeks. Components of the tests are described in the results. All analyses were performed by SRL Co., Ltd (Tokyo, Japan).</p>
              </sec>
              <sec id="Sec18">
                <title>Statistical analysis</title>
                <p id="Par34">Statistical analyses were performed by ORTHOMEDICO Inc. (Tokyo, Japan) using IBM SPSS Statistics version 23. Changes in numerical variables of each subject during the study period were analyzed by two-way factorial analysis of variance (ANOVA). Post-hoc analyses were performed by Fisher’s LSD or Dunnet’s test. Correlation between two numerical variables were analyzed by Pearson’s correlation coefficient test. Two average values of numerical variables were compared by t-test (two-sided). Average value was shown as the mean ± standard deviation. All statistical tests were two-sided; and significant difference was set at <italic>p</italic> &lt; 0.05.</p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors would like to thank Jan Dechent of Heidelberg Engineering Inc. for lending us a prototype MPOD module that was installed on our SPECTRALIS MultiColor platform. This work was supported by National Institutes of Health grants EY11600 and EY14800 (PSB) and a departmental grant from Research to Prevent Blindness (Moran Eye Center).</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>A.O. contributed conceptualization, formal analysis, investigating, methodology, writing original draft to this work. Y.G. and R.N. contributed investigation to this work. T.M. contributed data curation, project administration. W.G. and P.S.B. provided technical support for skin and ocular carotenoid measurements and edited the manuscript. All authors reviewed the manuscript.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par35">Gellermann W. is with Longevity Link Corporation and holds multiple patents on the use of reflection spectroscopy for the measurement of carotenoids in the skin, eye, and other tissues. Bernstein PS consults for Heidelberg Engineering Inc. Obana A., Gohto Y., Nakazawa R. and Moriyama T declare no competing Interests.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bone</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Landrum</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Hime</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Cains</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zamor</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Stereochemistry of the human macular carotenoids</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>1993</year>
                  <volume>34</volume>
                  <fpage>2033</fpage>
                  <lpage>2040</lpage>
                  <?supplied-pmid 8491553?>
                  <pub-id pub-id-type="pmid">8491553</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landrum</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Bone</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Lutein, zeaxanthin, and the macular pigment</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2001</year>
                  <volume>385</volume>
                  <fpage>28</fpage>
                  <lpage>40</lpage>
                  <pub-id pub-id-type="doi">10.1006/abbi.2000.2171</pub-id>
                  <?supplied-pmid 11361022?>
                  <pub-id pub-id-type="pmid">11361022</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krinsky</surname>
                      <given-names>NI</given-names>
                    </name>
                    <name>
                      <surname>Landrum</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Bone</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye</article-title>
                  <source>Annu. Rev. Nutr.</source>
                  <year>2003</year>
                  <volume>23</volume>
                  <fpage>171</fpage>
                  <lpage>201</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev.nutr.23.011702.073307</pub-id>
                  <?supplied-pmid 12626691?>
                  <pub-id pub-id-type="pmid">12626691</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krinsky</surname>
                      <given-names>NI</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>EJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Carotenoid actions and their relation to health and disease</article-title>
                  <source>Mol. Aspects Med.</source>
                  <year>2005</year>
                  <volume>26</volume>
                  <fpage>459</fpage>
                  <lpage>516</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mam.2005.10.001</pub-id>
                  <?supplied-pmid 16309738?>
                  <pub-id pub-id-type="pmid">16309738</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mortensen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Skibsted</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Sampson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rice-Evans</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Everett</surname>
                      <given-names>SA</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants</article-title>
                  <source>FEBS Lett.</source>
                  <year>1997</year>
                  <volume>418</volume>
                  <fpage>91</fpage>
                  <lpage>97</lpage>
                  <pub-id pub-id-type="doi">10.1016/s0014-5793(97)01355-0</pub-id>
                  <?supplied-pmid 9414102?>
                  <pub-id pub-id-type="pmid">9414102</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loughman</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The impact of macular pigment augmentation on visual performance using different carotenoid formulations</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2012</year>
                  <volume>53</volume>
                  <fpage>7871</fpage>
                  <lpage>7880</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.12-10690</pub-id>
                  <?supplied-pmid 23132800?>
                  <pub-id pub-id-type="pmid">23132800</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration</article-title>
                  <source>Ophthalmology</source>
                  <year>2012</year>
                  <volume>119</volume>
                  <fpage>2290</fpage>
                  <lpage>2297</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ophtha.2012.06.014</pub-id>
                  <?supplied-pmid 22858124?>
                  <pub-id pub-id-type="pmid">22858124</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stringham</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Garcia</surname>
                      <given-names>PV</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>McLin</surname>
                      <given-names>LN</given-names>
                    </name>
                    <name>
                      <surname>Foutch</surname>
                      <given-names>BK</given-names>
                    </name>
                  </person-group>
                  <article-title>Macular pigment and visual performance in glare: benefits for photostress recovery, disability glare, and visual discomfort</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2011</year>
                  <volume>52</volume>
                  <fpage>7406</fpage>
                  <lpage>7415</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.10-6699</pub-id>
                  <?supplied-pmid 21296819?>
                  <pub-id pub-id-type="pmid">21296819</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nolan</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Enrichment of Macular Pigment Enhances Contrast Sensitivity in Subjects Free of Retinal Disease: Central Retinal Enrichment Supplementation Trials - Report 1</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2016</year>
                  <volume>57</volume>
                  <fpage>3429</fpage>
                  <lpage>3439</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.16-19520</pub-id>
                  <?supplied-pmid 27367585?>
                  <pub-id pub-id-type="pmid">27367585</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beatty</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2001</year>
                  <volume>42</volume>
                  <fpage>439</fpage>
                  <lpage>446</lpage>
                  <?supplied-pmid 11157880?>
                  <pub-id pub-id-type="pmid">11157880</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>PS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients</article-title>
                  <source>Ophthalmology</source>
                  <year>2002</year>
                  <volume>109</volume>
                  <fpage>1780</fpage>
                  <lpage>1787</lpage>
                  <pub-id pub-id-type="doi">10.1016/s0161-6420(02)01173-9</pub-id>
                  <?supplied-pmid 12359594?>
                  <pub-id pub-id-type="pmid">12359594</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richer</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial)</article-title>
                  <source>Optometry (St. Louis, Mo.)</source>
                  <year>2004</year>
                  <volume>75</volume>
                  <fpage>216</fpage>
                  <lpage>230</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1529-1839(04)70049-4</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tan</surname>
                      <given-names>JS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study</article-title>
                  <source>Ophthalmology</source>
                  <year>2008</year>
                  <volume>115</volume>
                  <fpage>334</fpage>
                  <lpage>341</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ophtha.2007.03.083</pub-id>
                  <?supplied-pmid 17664009?>
                  <pub-id pub-id-type="pmid">17664009</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krishnadev</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Meleth</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Chew</surname>
                      <given-names>EY</given-names>
                    </name>
                  </person-group>
                  <article-title>Nutritional supplements for age-related macular degeneration</article-title>
                  <source>Curr. Opin. Ophthalmol.</source>
                  <year>2010</year>
                  <volume>21</volume>
                  <fpage>184</fpage>
                  <lpage>189</lpage>
                  <pub-id pub-id-type="doi">10.1097/ICU.0b013e32833866ee</pub-id>
                  <?supplied-pmid 20216418?>
                  <pub-id pub-id-type="pmid">20216418</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Piermarocchi</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study</article-title>
                  <source>Eur. J. Ophthalmol.</source>
                  <year>2012</year>
                  <volume>22</volume>
                  <fpage>216</fpage>
                  <lpage>225</lpage>
                  <pub-id pub-id-type="doi">10.5301/ejo.5000069</pub-id>
                  <?supplied-pmid 22009916?>
                  <pub-id pub-id-type="pmid">22009916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Obana</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macular carotenoid levels of normal subjects and age-related maculopathy patients in a Japanese population</article-title>
                  <source>Ophthalmology</source>
                  <year>2008</year>
                  <volume>115</volume>
                  <fpage>147</fpage>
                  <lpage>157</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ophtha.2007.02.028</pub-id>
                  <?supplied-pmid 18166409?>
                  <pub-id pub-id-type="pmid">18166409</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stahl</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Sies</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Bioactivity and protective effects of natural carotenoids</article-title>
                  <source>Biochim. Biophys. Acta</source>
                  <year>2005</year>
                  <volume>1740</volume>
                  <fpage>101</fpage>
                  <lpage>107</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbadis.2004.12.006</pub-id>
                  <?supplied-pmid 15949675?>
                  <pub-id pub-id-type="pmid">15949675</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morganti</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Role of topical and nutritional supplement to modify the oxidative stress</article-title>
                  <source>Int. J. Cosmet. Sci.</source>
                  <year>2002</year>
                  <volume>24</volume>
                  <fpage>331</fpage>
                  <lpage>339</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1467-2494.2002.00159.x</pub-id>
                  <?supplied-pmid 18494887?>
                  <pub-id pub-id-type="pmid">18494887</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alves-Rodrigues</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Shao</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>The science behind lutein</article-title>
                  <source>Toxicol. Lett.</source>
                  <year>2004</year>
                  <volume>150</volume>
                  <fpage>57</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.toxlet.2003.10.031</pub-id>
                  <?supplied-pmid 15068825?>
                  <pub-id pub-id-type="pmid">15068825</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henriksen</surname>
                      <given-names>BS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interrelationships between maternal carotenoid status and newborn infant macular pigment optical density and carotenoid status</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2013</year>
                  <volume>54</volume>
                  <fpage>5568</fpage>
                  <lpage>5578</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.13-12331</pub-id>
                  <?supplied-pmid 23838770?>
                  <pub-id pub-id-type="pmid">23838770</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <mixed-citation publication-type="other">Bernstein, P. S. Blue-Light Reflectance Imaging of Macular Pigment in Infants and Children. <italic>IOVS</italic> (2013).</mixed-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Conrady</surname>
                      <given-names>CD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Correlations Between Macular, Skin, and Serum Carotenoids</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2017</year>
                  <volume>58</volume>
                  <fpage>3616</fpage>
                  <lpage>3627</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.17-21818</pub-id>
                  <?supplied-pmid 28728169?>
                  <pub-id pub-id-type="pmid">28728169</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Obana</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Skin Carotenoid Index in a large Japanese population sample</article-title>
                  <source>Sci. Rep</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <fpage>9318</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-019-45751-6</pub-id>
                  <?supplied-pmid 31249340?>
                  <pub-id pub-id-type="pmid">31249340</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <mixed-citation publication-type="other">A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. <italic>Arch. Ophthalmol</italic>. <bold>119</bold>, 1417–1436, 10.1001/archopht.119.10.1417 (2001).</mixed-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Age-Related Eye Disease Study Research, G. <italic>et al</italic>. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. <italic>Arch. Ophthalmol</italic>. <bold>125</bold>, 1225–1232, 10.1001/archopht.125.9.1225 (2007).</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">Age-Related Eye Disease Study 2 Research, G. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. <italic>JAMA</italic><bold>309</bold>, 2005–2015, 10.1001/jama.2013.4997 (2013).</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <mixed-citation publication-type="other">SanGiovanni, J. P. <italic>et al</italic>. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. <italic>Arch. Ophthalmol</italic>. <bold>125</bold>, 1225–1232, 10.1001/archopht.125.9.1225 (2007).</mixed-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <mixed-citation publication-type="other">Age-Related Eye Disease Study 2 Research, G. et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. <italic>JAMA Ophthalmol</italic><bold>132</bold>, 142–149, 10.1001/jamaophthalmol.2013.7376 (2014).</mixed-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Connolly</surname>
                      <given-names>EE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Supplementation with all three macular carotenoids: response, stability, and safety</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2011</year>
                  <volume>52</volume>
                  <fpage>9207</fpage>
                  <lpage>9217</lpage>
                  <pub-id pub-id-type="doi">10.1167/iovs.11-8025</pub-id>
                  <?supplied-pmid 21979997?>
                  <pub-id pub-id-type="pmid">21979997</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Trieschmann</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study</article-title>
                  <source>Exp. Eye Res.</source>
                  <year>2007</year>
                  <volume>84</volume>
                  <fpage>718</fpage>
                  <lpage>728</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.exer.2006.12.010</pub-id>
                  <?supplied-pmid 17306793?>
                  <pub-id pub-id-type="pmid">17306793</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Obana</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements</article-title>
                  <source>Plos One</source>
                  <year>2015</year>
                  <volume>10</volume>
                  <fpage>e0139257</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0139257</pub-id>
                  <?supplied-pmid 26451726?>
                  <pub-id pub-id-type="pmid">26451726</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tanito</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macular pigment density changes in Japanese individuals supplemented with lutein or zeaxanthin: quantification via resonance Raman spectrophotometry and autofluorescence imaging</article-title>
                  <source>Jpn. J. Ophthalmol.</source>
                  <year>2012</year>
                  <volume>56</volume>
                  <fpage>488</fpage>
                  <lpage>496</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10384-012-0157-0</pub-id>
                  <?supplied-pmid 22699751?>
                  <pub-id pub-id-type="pmid">22699751</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landrum</surname>
                      <given-names>JT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A one year study of the macular pigment: the effect of 140 days of a lutein supplement</article-title>
                  <source>Exp. Eye Res.</source>
                  <year>1997</year>
                  <volume>65</volume>
                  <fpage>57</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="doi">10.1006/exer.1997.0309</pub-id>
                  <?supplied-pmid 9237865?>
                  <pub-id pub-id-type="pmid">9237865</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Berendschot</surname>
                      <given-names>TT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Influence of lutein supplementation on macular pigment, assessed with two objective techniques</article-title>
                  <source>Invest. Ophthalmol. Vis. Sci.</source>
                  <year>2000</year>
                  <volume>41</volume>
                  <fpage>3322</fpage>
                  <lpage>3326</lpage>
                  <?supplied-pmid 11006220?>
                  <pub-id pub-id-type="pmid">11006220</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koh</surname>
                      <given-names>HH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study</article-title>
                  <source>Exp. Eye Res.</source>
                  <year>2004</year>
                  <volume>79</volume>
                  <fpage>21</fpage>
                  <lpage>27</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.exer.2004.03.001</pub-id>
                  <?supplied-pmid 15183097?>
                  <pub-id pub-id-type="pmid">15183097</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Connolly</surname>
                      <given-names>EE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study</article-title>
                  <source>Curr. Eye Res.</source>
                  <year>2010</year>
                  <volume>35</volume>
                  <fpage>335</fpage>
                  <lpage>351</lpage>
                  <pub-id pub-id-type="doi">10.3109/02713680903521951</pub-id>
                  <?supplied-pmid 20373901?>
                  <pub-id pub-id-type="pmid">20373901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Johnson</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density</article-title>
                  <source>Am. J. Clin. Nutr.</source>
                  <year>2000</year>
                  <volume>71</volume>
                  <fpage>1555</fpage>
                  <lpage>1562</lpage>
                  <pub-id pub-id-type="doi">10.1093/ajcn/71.6.1555</pub-id>
                  <?supplied-pmid 10837298?>
                  <pub-id pub-id-type="pmid">10837298</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <mixed-citation publication-type="other">Juturu, V., Bowman, J. P., Stringham, N. T. &amp; Stringham, J. M. Bioavailability of lutein/zeaxanthin isomers and macular pigment optical density response to macular carotenoid supplementation: A randomized double blind placebo controlled study. <italic>New Frontiers in Ophthalmology</italic><bold>2</bold>, 10.15761/nfo.1000132 (2016).</mixed-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nolan</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macular pigment, visual function, and macular disease among subjects with Alzheimer’s disease: an exploratory study</article-title>
                  <source>J. Alzheimers Dis.</source>
                  <year>2014</year>
                  <volume>42</volume>
                  <fpage>1191</fpage>
                  <lpage>1202</lpage>
                  <pub-id pub-id-type="doi">10.3233/jad-140507</pub-id>
                  <?supplied-pmid 25024317?>
                  <pub-id pub-id-type="pmid">25024317</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Broekmans</surname>
                      <given-names>WM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin</article-title>
                  <source>Am. J. Clin. Nutr.</source>
                  <year>2002</year>
                  <volume>76</volume>
                  <fpage>595</fpage>
                  <lpage>603</lpage>
                  <pub-id pub-id-type="doi">10.1093/ajcn/76.3.595</pub-id>
                  <?supplied-pmid 12198005?>
                  <pub-id pub-id-type="pmid">12198005</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <mixed-citation publication-type="other">Obana, A. <italic>et al</italic>. Spatial distribution of macular pigment estimated by autofluorescence imaging in elderly Japanese individuals. <italic>Jpn. J. Ophthalmol</italic>, in print (2020).</mixed-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Green-Gomez</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Standardizing the Assessment of Macular Pigment Using a Dual-Wavelength Autofluorescence Technique</article-title>
                  <source>Transl Vis Sci Technol</source>
                  <year>2019</year>
                  <volume>8</volume>
                  <fpage>41</fpage>
                  <pub-id pub-id-type="doi">10.1167/tvst.8.6.41</pub-id>
                  <?supplied-pmid 31867142?>
                  <pub-id pub-id-type="pmid">31867142</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <mixed-citation publication-type="other">Gellermann, W. Raman detection of carotenoids in human tissue in Carotenoids and Retinoids: Molecular Aspects and Health Issues. (2005).</mixed-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zidichouski</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Mastaloudis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Poole</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Reading</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Smidt</surname>
                      <given-names>CR</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical validation of a noninvasive, Raman spectroscopic method to assess carotenoid nutritional status in humans</article-title>
                  <source>J. Am. Coll. Nutr.</source>
                  <year>2009</year>
                  <volume>28</volume>
                  <fpage>687</fpage>
                  <lpage>693</lpage>
                  <pub-id pub-id-type="doi">10.1080/07315724.2009.10719802</pub-id>
                  <pub-id pub-id-type="pmid">20516269</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Darvin</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dermal carotenoid level and kinetics after topical and systemic administration of antioxidants: enrichment strategies in a controlled <italic>in vivo</italic> study</article-title>
                  <source>J. Dermatol. Sci.</source>
                  <year>2011</year>
                  <volume>64</volume>
                  <fpage>53</fpage>
                  <lpage>58</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jdermsci.2011.06.009</pub-id>
                  <?supplied-pmid 21763110?>
                  <pub-id pub-id-type="pmid">21763110</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ermakov</surname>
                      <given-names>IV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Optical assessment of skin carotenoid status as a biomarker of vegetable and fruit intake</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2018</year>
                  <volume>646</volume>
                  <fpage>46</fpage>
                  <lpage>54</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2018.03.033</pub-id>
                  <?supplied-pmid 29601824?>
                  <pub-id pub-id-type="pmid">29601824</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scarmo</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Significant correlations of dermal total carotenoids and dermal lycopene with their respective plasma levels in healthy adults</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2010</year>
                  <volume>504</volume>
                  <fpage>34</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2010.07.004</pub-id>
                  <?supplied-pmid 20637178?>
                  <pub-id pub-id-type="pmid">20637178</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ermakov</surname>
                      <given-names>IV</given-names>
                    </name>
                    <name>
                      <surname>Gellermann</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Validation model for Raman based skin carotenoid detection</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2010</year>
                  <volume>504</volume>
                  <fpage>40</fpage>
                  <lpage>49</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2010.07.023</pub-id>
                  <?supplied-pmid 20678465?>
                  <pub-id pub-id-type="pmid">20678465</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>LM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evaluating the relationship between plasma and skin carotenoids and reported dietary intake in elementary school children to assess fruit and vegetable intake</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2015</year>
                  <volume>572</volume>
                  <fpage>73</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2015.02.015</pub-id>
                  <?supplied-pmid 25765187?>
                  <pub-id pub-id-type="pmid">25765187</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jahns</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Skin and plasma carotenoid response to a provided intervention diet high in vegetables and fruit: uptake and depletion kinetics</article-title>
                  <source>Am. J. Clin. Nutr.</source>
                  <year>2014</year>
                  <volume>100</volume>
                  <fpage>930</fpage>
                  <lpage>937</lpage>
                  <pub-id pub-id-type="doi">10.3945/ajcn.114.086900</pub-id>
                  <?supplied-pmid 25008856?>
                  <pub-id pub-id-type="pmid">25008856</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aguilar</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Wengreen</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Lefevre</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Madden</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Gast</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Skin carotenoids: a biomarker of fruit and vegetable intake in children</article-title>
                  <source>J. Acad. Nutr. Diet.</source>
                  <year>2014</year>
                  <volume>114</volume>
                  <fpage>1174</fpage>
                  <lpage>1180</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jand.2014.04.026</pub-id>
                  <?supplied-pmid 24951435?>
                  <pub-id pub-id-type="pmid">24951435</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ermakov</surname>
                      <given-names>IV</given-names>
                    </name>
                    <name>
                      <surname>Ermakova</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Gellermann</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Resonance Raman based skin carotenoid measurements in newborns and infants</article-title>
                  <source>J Biophotonics</source>
                  <year>2013</year>
                  <volume>6</volume>
                  <fpage>793</fpage>
                  <lpage>802</lpage>
                  <pub-id pub-id-type="doi">10.1002/jbio.201200195</pub-id>
                  <?supplied-pmid 23193015?>
                  <pub-id pub-id-type="pmid">23193015</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mayne</surname>
                      <given-names>ST</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Noninvasive assessment of dermal carotenoids as a biomarker of fruit and vegetable intake</article-title>
                  <source>Am. J. Clin. Nutr.</source>
                  <year>2010</year>
                  <volume>92</volume>
                  <fpage>794</fpage>
                  <lpage>800</lpage>
                  <pub-id pub-id-type="doi">10.3945/ajcn.2010.29707</pub-id>
                  <?supplied-pmid 20685953?>
                  <pub-id pub-id-type="pmid">20685953</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>PS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease</article-title>
                  <source>Prog. Retin. Eye Res.</source>
                  <year>2016</year>
                  <volume>50</volume>
                  <fpage>34</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.preteyeres.2015.10.003</pub-id>
                  <?supplied-pmid 26541886?>
                  <pub-id pub-id-type="pmid">26541886</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choi</surname>
                      <given-names>RY</given-names>
                    </name>
                    <name>
                      <surname>Chortkoff</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Gorusupudi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>PS</given-names>
                    </name>
                  </person-group>
                  <article-title>Crystalline Maculopathy Associated With High-Dose Lutein Supplementation</article-title>
                  <source>JAMA Ophthalmol</source>
                  <year>2016</year>
                  <volume>134</volume>
                  <fpage>1445</fpage>
                  <lpage>1448</lpage>
                  <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2016.4117</pub-id>
                  <?supplied-pmid 27787539?>
                  <pub-id pub-id-type="pmid">27787539</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schalch</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2007</year>
                  <volume>458</volume>
                  <fpage>128</fpage>
                  <lpage>135</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2006.09.032</pub-id>
                  <?supplied-pmid 17084803?>
                  <pub-id pub-id-type="pmid">17084803</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>You</surname>
                      <given-names>QS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reproducibility of Macular Pigment Optical Density Measurement by Two-Wavelength Autofluorescence in a Clinical Setting</article-title>
                  <source>Retina</source>
                  <year>2016</year>
                  <volume>36</volume>
                  <fpage>1381</fpage>
                  <lpage>1387</lpage>
                  <pub-id pub-id-type="doi">10.1097/IAE.0000000000000893</pub-id>
                  <?supplied-pmid 26655614?>
                  <pub-id pub-id-type="pmid">26655614</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Obana</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reliability of a two-wavelength autofluorescence technique by Heidelberg Spectralis to measure macular pigment optical density in Asian subjects</article-title>
                  <source>Exp. Eye Res.</source>
                  <year>2018</year>
                  <volume>168</volume>
                  <fpage>100</fpage>
                  <lpage>106</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.exer.2017.12.015</pub-id>
                  <?supplied-pmid 29357284?>
                  <pub-id pub-id-type="pmid">29357284</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ermakov</surname>
                      <given-names>IV</given-names>
                    </name>
                    <name>
                      <surname>Gellermann</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Dermal carotenoid measurements via pressure mediated reflection spectroscopy</article-title>
                  <source>J Biophotonics</source>
                  <year>2012</year>
                  <volume>5</volume>
                  <fpage>559</fpage>
                  <lpage>570</lpage>
                  <pub-id pub-id-type="doi">10.1002/jbio.201100122</pub-id>
                  <?supplied-pmid 22331637?>
                  <pub-id pub-id-type="pmid">22331637</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ermakov</surname>
                      <given-names>IV</given-names>
                    </name>
                    <name>
                      <surname>Gellermann</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Optical detection methods for carotenoids in human skin</article-title>
                  <source>Arch. Biochem. Biophys.</source>
                  <year>2015</year>
                  <volume>572</volume>
                  <fpage>101</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.abb.2015.01.020</pub-id>
                  <?supplied-pmid 25637655?>
                  <pub-id pub-id-type="pmid">25637655</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
